BioCentury | Jun 5, 2020
Finance

With $85M series B, Athira seeks to recover neuronal health in Alzheimer’s patients

...Formed in 2011, Athira was built on research from co-founder Joe Harding that suggested targeting HGF/SF...
...peripheral neuropathy and pain. Perceptive Advisors’ Joseph Edelman will join the board. Targets HGF/SF - Hepatocyte growth factor/scatter factor...
...c-Met receptor tyrosine kinase Elizabeth S. Eaton, Staff Writer c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) Hepatocyte growth factor/scatter factor (HGF/SF) Athira...
BioCentury | May 26, 2020
Distillery Therapeutics

DNA-based HGF/SF mimetic for hepatitis

...DISEASE CATEGORY: Infectious disease INDICATION: Hepatitis An oligonucleotide-based mimetic of HGF/SF, a growth factor that can...
...and have the product in Phase III testing for peripheral vascular disease (PVD). TARGET/MARKER/PATHWAY: Hepatocyte growth factor/scatter factor (HGF/SF...
...Japan email: r.ueki@chembio.t.u-tokyo.ac.jp CONTACT: Shinsuke Sando, same affiliation as above email: ssando@chembio.t.u-tokyo.ac.jp Claire Quang University of Tokyo Hepatocyte growth factor/scatter factor (HGF/SF...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...inflammatory cells; "may provide a clinically significant survival" 2019 YooYoung Pharmaceutical Co. Ltd. YYB101 Anti-hepatocyte growth factor/scatter factor (HGF/SF...
BioCentury | Apr 3, 2019
Financial News

AgomAb emerges from stealth with €21M series A

...Paolo Michieli's lab at the university studying hepatocyte growth factor/scatter factor (HGF/SF) and its role in cancer metabolism. HGF/SF...
...antibodies that can overcome these limitations, he added. The company has unpublished preclinical data showing HGF/SF...
...in the company, participating in AgomAb's undisclosed seed round. Mary Romeo, Staff Writer argenx S.E. Omnes Capital Pontifax V-Bio Ventures Hepatocyte growth factor/scatter factor (HGF/SF) Advent...
BioCentury | Mar 19, 2019
Preclinical News

Merrimack develops bispecific against c-MET oncogene

...are not potent enough and bivalent antibodies activate instead of block c-MET when its ligand, HGF/SF...
...in solid cancer cell lines more potently than a monovalent anti-c-MET antibody, whether or not HGF/SF...
...Epithelial cell adhesion molecule; HER1 (EGFR; ErbB1) - Epidermal growth factor receptor; HGF/SF - Hepatocyte growth factor/scatter factor Sandi...
BioCentury | Dec 5, 2018
Distillery Techniques

Disease models

...them. The organoids are generated by culturing human placenta-derived trophoblasts in culture media with hepatocyte growth factor/scatter factor (HGF/SF...
BioCentury | Nov 30, 2018
Company News

Sinovant gains Chinese rights to Angion's BB3

...with Sinovant taking the lead in the licensed territories. BB3 is a small molecule hepatocyte growth factor/scatter factor (HGF/SF...
...Corp., Uniondale, N.Y. Sinovant Sciences Ltd., Beijing, China Business: Hepatic Shannon Lehnbeuter BB3 Angion Biomedica Corp. Sinovant Sciences Ltd. Hepatocyte growth factor/scatter factor (HGF/SF...
BioCentury | Feb 16, 2018
Clinical News

Molecular Partners reports Phase II data for MP0250 in MM

...hepatocyte growth factor/scatter factor (HGF/SF). Molecular Partners AG (SIX:MOLN), Schlieren, Switzerland Product: MP0250 Business: Cancer Molecular target: VEGF; Hepatocyte growth factor/scatter factor...
...Molecular target: VEGF; Hepatocyte growth factor/scatter factor (HGF/SF) Description: Designed ankyrin repeat protein (DARPin) that inhibits VEGF and HGF/SF...
...Phase II data Milestone: Additional Phase II data (year end 2018) Jaime De Leon MP0250 Molecular Partners AG Hepatocyte growth factor/scatter factor (HGF/SF) VEGF...
BioCentury | Jun 9, 2017
Clinical News

Aveo reports Phase I data for ficlatuzumab in SCCHN

...and Biodesix Inc. (Boulder, Colo.) are co-developing ficlatuzumab, a human IgG1 mAb antagonist of the hepatocyte growth factor/scatter factor...
...AV-299 ) Business: Cancer Molecular target: Hepatocyte growth factor/scatter factor (HGF/SF) Description: Human IgG1 mAb antagonist of the HGF/SF...
...QOL) Status: Phase I data Milestone: NA Julian Zhu AV-299 ficlatuzumab American Society of Clinical Oncology Aveo Pharmaceuticals Inc. Biodesix Inc. Hepatocyte growth factor/scatter factor (HGF/SF) ASCO...
BioCentury | Jun 9, 2017
Clinical News

Aveo reports Phase I data for ficlatuzumab in AML

...and Biodesix Inc. (Boulder, Colo.) are co-developing ficlatuzumab, a human IgG1 mAb antagonist of the hepatocyte growth factor/scatter factor...
...AV-299 ) Business: Cancer Molecular target: Hepatocyte growth factor/scatter factor (HGF/SF) Description: Human IgG1 mAb antagonist of the HGF/SF...
...biomarkers Status: Phase I data Milestone: NA Julian Zhu AV-299 ficlatuzumab American Society of Clinical Oncology Aveo Pharmaceuticals Inc. Biodesix Inc. Hepatocyte growth factor/scatter factor (HGF/SF) ASCO...
Items per page:
1 - 10 of 100